HDAC9 and metastatic melanoma: Moreover, candidate metastasis-related biomarkers were validated in early-passage cultures of patient-derived metastatic melanoma cell lines as well as primary melanocytes untreated and/or previously treated with 5AzaCdR in combination to the HDAC inhibitor Trichostatin A (TSA) (Figure 5B-5E, Figure 6).